← SynDRA
MIDOSTAURIN
SynDRA canonical compound SYN0020744 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | KIT |
|---|
| Mechanism of action | FLT3 inhibitor |
|---|
| Indication | acute myeloid leukemia (AML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- FLT3
- KIT
- KDR
- PRKCA
- PDGFRB
- PRKCG
- PDGFRA
- PRKD3
- PRKCQ
- PRKCH
- PRKCE
- PRKCD
Mechanisms of action (all sources)
- KIT INHIBITOR
- PKC inhibitor
- FLT3 INHIBITOR
- Tyrosine-protein kinase receptor FLT3 inhibitor
- Stem cell growth factor receptor inhibitor
- PDGFRB INHIBITOR
- Platelet-derived growth factor receptor inhibitor
- PDGFRA INHIBITOR
- PRKD3 INHIBITOR
- Protein kinase C (PKC) inhibitor
- PRKCI INHIBITOR
- PRKCA INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCB1
- CDK12
- ABCG2
- CDK9
- CDK7
- CDK2
- YJ005
- ACVR1
- PAK6
- NEK5
- NEK6
- NEK7
- NEK9
- NIM1K
- NLK
- NQO2
- OLA1
- OPA1
- OXSR1
- PAICS
- PAK4
- PAK5
- PASK
- NEK3
- PDXK
- PEBP1
- PFKP
- PI4KB
- PIK3CB
- PIK3CD
- PIK3CG
- PIP4K2C
- PIP5K1C
- PKMYT1
- PLK1
- PLK2
- PLK3
- NEK4
- NEK2
- ACVR1B
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CCNE1
- CCNH
- CCNK
- CCNT1
- IFNG
- KSYK
- NSD2
- PARP1
Drug classes
- Receptor Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitor
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- RYDAPT
- Rydapt
- CGP 41251
- PKC 412
- rydapt
- Midostaurine
- Midostaurina
- N-benzoylstaurosporine
- PKC-412
- CGP-41251
- NSC-656576
- NVP-PKC412
- PKC412
- 4'-N-Benzoylstaurosporine
- Benzoylstaurosporine
- UNII-ID912S5VON
- N-Benzoylstaurosporine
- ID912S5VON
- CHEMBL608533
- CHEBI:63452
- Cgp 41 251
- PKC-412(Midostaurin)
- Midostaurin (PKC412)
- Midostaurin (USAN/INN)
- Midostaurin [USAN:INN]
- CGP 41231
- Rydapt (TN)
- CPG 41251
- NSC 656576
- Midostaurin [INN]
- Midostaurin(PKC412)
- 4-N-benzoylstaurosporine
- MIDOSTAURIN [MI]
- Staurosporine, N-Benzoyl
- MIDOSTAURIN [JAN]
- MIDOSTAURIN [USAN]
- MIDOSTAURIN [MART.]
Reported adverse events
- Abdominal pain
- Activated partial thromboplastin time prolonged
- Acute febrile neutrophilic dermatosis
- Arthralgia
- Chills
- Constipation
- Cough
- Disturbance in attention
- Dizziness
- Dry skin
- Dyspepsia
- Electrocardiogram QT prolonged
Look up MIDOSTAURIN in the interactive SynDRA portal →